Description

Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin light chain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca2+ entry. Myosin light chain kinase fragment 11-19 amide can be used in the research of human cervical cancer[1][2].—–C40H78N18O11—-[1]Aromolaran AS, et al. Evidence for myosin light chain kinase mediating noradrenaline-evoked cation current in rabbit portal vein myocytes. J Physiol. 2000 May 1;524 Pt 3(Pt 3):853-63. |[2]Shen MR, et al. Myosin light chain kinase modulates hypotonicity-induced Ca2+ entry and Cl- channel activity in human cervical cancer cells. Pflugers Arch. 2002 May;444(1-2):276-85. |[3]Chilcoat CD, et al. Tonic protein kinase A activity maintains inactive beta2 integrins in unstimulated neutrophils by reducing myosin light-chain phosphorylation: role of myosin light-chain kinase and Rho kinase. J Leukoc Biol. 2008 Apr;83(4):964-71. –119386-39-9–987.16—-NCCCC[C@H](N)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer–10 mM in DMSO–Others—-Others–Peptides